15 stocks pre-market positive announcement express on January 9
Sifangda's 2019 net profit is expected to increase by 78% -94%
Sifangda disclosed the 2019 annual results forecast. The company expects a profit of 115 million to 125 million yuan in 2019, an increase of 78% -94% over the same period last year.
Tiankang Bio's hog sales revenue in 2019 increased by 111% year-on-year
Tiankang Bio announced that the company sold 73,100 live pigs in December 2019, with sales volume increasing by 20.23% month-on-month and 0.83% year-on-year; sales income of 264 million yuan, sales income increasing by 44.26% month-on-year and 214.29% year-on-year. From January to December 2019, the company sold a total of 842,700 pigs, an increase of 30.33% over the same period last year; the cumulative sales income was 1,501 million yuan, an increase of 110.81% over the same period last year.
Shanghai Construction Engineering's spin-off subsidiary Construction Engineering Materials was listed on the main board of the Shanghai Stock Exchange. Shanghai Construction Engineering announced that the company's wholly-owned subsidiary, Shanghai Construction Engineering Materials Engineering Co., Ltd. and related entities, after appropriate reorganization, changed the entire construction engineering materials to form a joint stock company. It also submitted the listing application documents to the China Securities Regulatory Commission as the subject to be listed. After obtaining the approval, it chose to publicly issue A shares and listed on the main board of the Shanghai Stock Exchange. The main business of the main construction materials of this spin-off is the production and sales of ready-mixed concrete, prefabricated components and other materials. It belongs to the business sector of the building materials industry and maintains a high degree of independence from other business segments of the company. After the completion of the spin-off, construction materials are still the company's controlling subsidiaries.
Aier Ophthalmology intends to acquire multiple eye hospitals with a total price of 1.87 billion yuan. Aier Ophthalmology announced that the company intends to purchase 100% equity of Tianjin Cvision by issuing shares, and intends to purchase 100% equity of Allied Vision by issuing shares and paying cash. And Xuancheng Eye Hospital 80% equity, it is planned to purchase 90% equity of Wanzhou Airi and 90% equity of Kaizhou Airi by way of issuing shares, and the transaction price of these equity amounts to RMB 18,898,800. At the same time, the company intends to raise matching funds by issuing shares to no more than 5 specific investors, with the total amount of matching funds not exceeding RMB 710.2 million. This transaction constitutes a major asset reorganization. The company intends to acquire multiple eye hospitals, which is an expansion of the company's original business and will help achieve its own business synergy.
Yibai Pharmaceutical intends to invest 600 million yuan in the construction of a new plant in Mei'an Science and Technology City to expand the production capacity of anti-tumor drugs Growing market demand for third-generation platinum-based antitumor drugs for injection of loplatin. In order to solve the bottleneck of development and to increase the company's production capacity of chemical drugs including anti-tumor drugs, Chang'an Pharmaceutical plans to invest in the construction of the "Meian Technology New City New Plant Construction Project" in Mei'an Science and Technology New City, Haikou After completion, it will be engaged in the production and operation of related products. The total investment in fixed assets of this project is expected to be 603 million yuan.